Hydroxyapatite for Dentin Hypersensitivity

Hydroxyapatite toothpaste, usually with nano-sized particles, has the strongest evidence of its uses for dentin hypersensitivity. A meta-analysis of six randomized trials found nano-hydroxyapatite treatments relieved sensitivity more than other treatments or placebo over 4 weeks (SMD -0.93, 95% CI -1.19 to -0.68), rated high-quality evidence for the pooled result, although cold-stimulus pain did not differ (de Melo Alencar 2019). A larger review of 44 trials put the reduction at 39.5% versus placebo and 23% versus fluoride, with no significant advantage over other desensitizing agents (Limeback 2023).

The caveats matter. The 125-trial network meta-analysis found hydroxyapatite helpful only combined with potassium, with wide intervals (Martins 2020), and the 32-trial 2023 analysis recommended stannous, potassium and arginine toothpastes instead (Pollard 2023). So hydroxyapatite is a reasonable option, particularly for people who want a fluoride-free paste, but not the proven best. If you grind your teeth, see teeth grinding for the wear connection.

Dentin hypersensitivity needs exposed dentin and open tubules. The hydrodynamic theory, the most widely accepted explanation, says cold, air, touch or sweet and acidic stimuli move fluid in the tubules and activate nerve endings in the tooth (review PMC13086383). Hydroxyapatite is the mineral dentin is built from, and laboratory studies show it can block the tubule openings; clinical trials are what test whether that translates into less pain (Limeback 2023).

Tubule plugging in the lab does not mean durable relief in the mouth, where brushing, acids and saliva wear deposits away. The trials here mostly stopped at 4 to 8 weeks, so how long the effect lasts without continued use is unknown. Other active ingredients work by calming the nerve (potassium) or forming a mineral layer (calcium sodium phosphosilicate, stannous fluoride), and the network meta-analyses suggest several of them are at least as effective (Martins 2020).

In the main trials people brushed for 2 minutes twice a day with a fluoride-free toothpaste containing 15% nano-hydroxyapatite (Vano 2014); a 2% gel was left on the teeth for 10 minutes twice daily (Vano 2018); and a trial compared 10% and 15% pastes and a 10% paste with potassium nitrate, used at least twice daily for 8 weeks (Amaechi 2021). The zinc-carbonate hydroxyapatite paste in the Orsini trial was assessed at 4 and 8 weeks.

The EU Scientific Committee on Consumer Safety judged nano-hydroxyapatite safe up to 29.5% in toothpaste and 10% in mouthwash, for the specific particle type it assessed (SCCS 2025). Concentrations on labels are not always stated, so compare the ingredient list and the percentage where given.

The 2019 meta-analysis pooled six randomized trials with 4 weeks of follow-up. Overall SMD was -0.93 (95% CI -1.19 to -0.68, P < 0.00001), with SMD -1.09 for evaporative and -0.93 for tactile stimuli, but only -0.17 (95% CI -0.81 to 0.48, P = 0.61) for cold; the authors called for long-term trials (de Melo Alencar 2019). The 2023 review of 44 clinical trials found hydroxyapatite reduced sensitivity by 39.5% versus placebo (95% CI 30.06 to 48.93) and 23% versus fluoride (95% CI 11.82 to 34.18), with a non-significant 10.2% edge over other desensitizers (Limeback 2023). The review's authors also appear on several of the underlying hydroxyapatite trials, so independent replication is limited.

In two 105-person trials, a 15% nano-hydroxyapatite toothpaste and a 2% gel each lowered cold-air sensitivity, tactile sensitivity and visual analogue scale scores more than fluoride toothpaste or placebo after 2 and 4 weeks (Vano 2014; Vano 2018). An 8-week trial of three pastes (10%, 15%, and 10% with potassium nitrate) found all reduced sensitivity from baseline (P < 0.001); the 15% and the 10% plus potassium nitrate pastes did not differ significantly from a calcium sodium phosphosilicate product at any time point (Amaechi 2021).

In 70 adults, a zinc-carbonate hydroxyapatite toothpaste cut air-blast scores by 46.0% versus 29.4% with a sodium fluoride and potassium nitrate paste, and subjective scores by 47.5% versus 28.1%, while tactile and cold-water tests did not differ (Orsini 2010).

A network meta-analysis of 125 randomized trials (12,541 patients) found potassium plus hydroxyapatite superior to fluoride for tactile (SMD 2.47, 95% CI 0.3 to 4.64) and air stimuli (SMD 2.44, 95% CI 0.33 to 4.55), but with wide intervals; calcium sodium phosphosilicate was most beneficial across all stimuli (Martins 2020). The 2023 network meta-analysis of 32 trials recommended stannous, potassium (with or without stannous) and arginine dentifrices and did not name hydroxyapatite (Pollard 2023).

One small randomized trial in 21 children with molar incisor hypomineralisation, a developmental enamel defect, showed non-inferiority of a microcrystalline hydroxyapatite toothpaste to amine fluoride in the intention-to-treat analysis (difference -0.75, upper limit 0.49) but not in the per-protocol analysis (-0.62, upper limit 1.08 against a margin of 1), with only 14 of 21 children finishing; the hydroxyapatite group tended to be less sensitive in both (Ehlers 2021). Cold-stimulus pain did not differ in the pooled analysis either (de Melo Alencar 2019).

What's missing: trials longer than 8 weeks, comparisons with the best-ranked stannous and arginine pastes, and trials by groups unconnected to the products.

Hydroxyapatite toothpaste is a topical product. In cell models of the mouth lining, the EU committee found nano-hydroxyapatite did not cause mutagenic, cytotoxic or inflammatory effects even at high concentrations, and judged uptake by the mouth lining negligible (SCCS 2025). That opinion covers only uncoated rod-shaped particles of about 120 nm and does not cover needle-shaped or coated particles.

The authors of a 2024 review describe hydroxyapatite as safe if swallowed, which is why it is promoted for young children, but that view comes from authors who also run the hydroxyapatite trials (Pawinska 2024). Sensitivity can also be a sign of a cavity, a crack or gum disease, which toothpaste will not fix.

No drug interactions are documented for hydroxyapatite toothpaste. The practical questions are about other oral products.